Strong Top-Line Growth
First quarter revenue of $71 million, an approximately 45% year-over-year increase, driven by strong Amtagvi demand.
Iovance Biotherapeutics
· IOVA
May 7th, 2026
Summary
- Earnings Call Date:
- 2026-05-07
- Change Since:
- +19.72%
- Next Earnings Date:
- 2026-08-06
Earnings Call Sentiment
PositiveThe call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.
Company Guidance
Iovance provided tight near‑term and full‑year financial guidance and several supporting metrics: Q1 revenue was $71M (≈45% YoY), driven by Amtagvi $60M (↑38% YoY) and Proleukin $11M; gross‑to‑net remained <2% and Q1 gross margin was ~41% (affected by one‑time facility upgrade costs); R&D expense declined for a third consecutive quarter (‑18% vs prior period, ‑12% vs prior quarter); cash & equivalents were ~$319M at March 31 with management expecting to fund operations into 2028. For Q2 they forecast total revenue of $86–88M (Amtagvi $79–81M, roughly a 23% increase versus their prior highest quarterly Amtagvi revenue in Q4 2025), and full‑year 2026 revenue of $350–370M (Amtagvi + Proleukin), with margins expected to trend higher in 2026 excluding one‑time items; management also reiterated a >$1B U.S. peak sales trajectory for Amtagvi + Proleukin, noted March was the largest Amtagvi month to date, physician awareness rose to 70% (from 50% six months earlier), and the company is targeting roughly 110 ATCs by year‑end.
Amtagvi Commercial Momentum
Amtagvi revenue of $60 million in Q1, up ~38% year-over-year and the company's second-highest quarterly Amtagvi result; March was the largest month ever for reported Amtagvi revenue.
Tight Q2 and Full-Year Revenue Guidance
Q2 total revenue guidance of $86M–$88M with Amtagvi expected at $79M–$81M (an ~23% increase versus the company's prior highest quarterly revenue); full-year 2026 guidance of $350M–$370M for Amtagvi and Proleukin.
Improving Financial Discipline and Runway Extension
Research and development expense declined for the third consecutive quarter (down 18% versus the prior period and 12% versus the prior quarter); cash and equivalents of ~$319M as of March 31 with expectation to fund operations into 2028.
Manufacturing Control and Capacity Restoration
Completed maintenance upgrades at internal iCTC manufacturing facility; Amtagvi is now exclusively manufactured in-house with a modular facility designed to provide uninterrupted supply and support global scale.
Favorable Unit Economics Signals
Reported gross-to-net impact remains below 2%; Q1 gross margin from cost of sales ~41% despite one-time upgrade costs and management expects margins to trend higher for the remainder of 2026 excluding one-time items.
Clinical and Pipeline Advances
Announced compelling early Phase II data in metastatic serous endometrial cancer with a confirmed objective response rate (ORR) of 40% and 100% disease control rate in first five patients; pursuing FDA engagement for expedited approval.
Broad Registrational and Next-Generation Programs
Progress across registrational trials and next-gen candidates: TILVANCE-301 (frontline melanoma) ongoing; lifileucel Fast Track in previously treated non-squamous NSCLC targeting accelerated approval and potential H2 2027 launch; IOV-SAR-201 (soft tissue sarcoma) enrollment beginning Q3 2026; IOV-5001 IND submitted (Phase I/II expected H2 2026); IOV-3001 and IOV-4001 advancing.
Commercial Reach and Awareness Growth
ATC network expanding (targeting ~110 by year-end) and physician awareness increased from 50% to 70% over the prior six months; first ex-U.S. treatment center authorized in Canada with regulatory progress planned in Australia (H1) and Switzerland (next year).
Operator
Good day, and thank you for standing by. Welcome to the Iovance Biotherapeutics first quarter 2026 financial results conference call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Sara Pellegrino, SVP of Investor Relations and Corporate Communications. Please go ahead.
Sara Pellegrino
Thank you, operator. Good morning, welcome to the Iovance webcast to discuss our first quarter 2026 financial results, business achievements, and corporate updates. This morning, we issued a press release that is available on our corporate website at iovance.com. This conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, clinical trials and results, regulatory approvals, submissions, feedback and guidance, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, payer interactions, licenses and collaboration, cash position and expense guidance, and future updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statement. I will now turn the call over to Dr.
Fred Vogt, our Interim Chief Executive Officer and...
Subscribe to unlock transcripts
Get The Fly Pro 7 days for free